← Markets

Intellia Therapeutics, Inc.

NTLA · NASDAQ

Market closed$11.38$-0.485000 (-4.09%)After hours $11.49 · +1.01%

Key statistics

Previous close$11.86
Open$11.71
Day high$11.84
Day low$11.35
52-week high$28.25
52-week low$7.95
Market cap1.28B
Volume4.32M
Average volume6.95M
P/E ratio-3.20
Forward P/E—
EPS-3.55
Dividend yield0.00%

Market context

Why it moved

NTLA is pulling back today following its dramatic surge driven by positive Phase 3 trial results for its gene-editing hereditary angioedema therapy, with the stock giving back gains amid profit-taking pressure and a recent Sell rating issued by Wolfe Research with a price target well below current levels.

StocktwitsStocktwitsMarketbeatGovStocktwits

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Intellia Therapeutics fell sharply, extending a steep week-long decline as a Wolfe Research downgrade to Underperform with a $9 price target — implying roughly 30% further downside from today's close — weighed on sentiment. Analyst Andy Chen cited valuation concerns, framing the stock's HAE floor value at just $6/share with residual TTR value near post-liver-safety-event lows, a stark contrast to bullish targets from Canaccord ($49) and H.C. Wainwright ($25). The stock has now shed over 22% in the past week despite the FDA lifting clinical holds on its nex-z MAGNITUDE trials and the positive HAELO Phase 3 data, with 38% short interest amplifying volatility. Shares edged back toward $11.49 in after-hours trading.

-4.0894

July 17, 2026Intellia Therapeutics tumbled nearly 9% after Wolfe Research downgraded the stock to Underperform with a bearish $9 price target — implying roughly 30% further downside from the close — citing valuation concerns and setting an HAE floor value of just $6 per share plus residual TTR value. The downgrade compounds a rough stretch for NTLA, which had already fallen over 15% in the prior week and extended a 22% seven-day decline. The bearish call stands in stark contrast to more optimistic views from Canaccord Genuity ($49 target), H.C. Wainwright ($25), and Citizens ($30), all of whom maintained Buy-equivalent ratings on the strength of Phase 3 HAELO trial data showing lonvo-z reduced HAE attacks by 87%. Shares edged back up 1.4% in after-hours trading.

-9.0491

July 16, 2026Intellia Therapeutics shares declined amid a bearish analyst note from Wolfe Research, which downgraded the stock to Sell with a $9 price target — implying roughly 30% further downside from current levels. A Seeking Alpha article published Tuesday also argued the company is "considerably overvalued" given the commercial prospects of its two lead assets, lonvo-z and Nex-z. While Intellia generated significant excitement earlier this year around the first-ever Phase 3 readout of an in-vivo CRISPR therapy (lonvo-z for hereditary angioedema), the post-catalyst sentiment has since cooled, and the stock extended losses in after-hours trading.

-1.9549

July 15, 2026Intellia Therapeutics shares gained over 2% on Monday, outperforming a broadly mixed healthcare sector, as investors continued to digest pipeline progress from its gene-editing programs. A Seeking Alpha article published today raised concerns about Intellia being overvalued, citing regulatory, safety, and commercial hurdles for its lead candidates lonvo-z (hereditary angioedema) and Nex-z (ATTR amyloidosis), along with cash burn and dilution risks. Still, the stock held firm—buoyed by broader market optimism following a cooler-than-expected June CPI report and earlier positive clinical momentum.

2.1505

July 14, 2026Intellia Therapeutics shares tumbled roughly 8.5% as broad risk-off sentiment weighed on biotech names amid renewed U.S.-Iran military tensions that sent oil prices surging and rattled equity markets globally. The sell-off came despite a generally bullish backdrop for biotech—Goldman Sachs recently highlighted rising M&A momentum and strong fundamentals in the sector—and elevated short interest in NTLA (36.5% of float as of June 30) amplified the move. Investors continue to monitor the company's FDA submission timeline for its HAE therapy lonvoguran ziclumeran, with approval expected in the second half of 2026.

-8.4388

July 11, 2026Intellia Therapeutics tumbled nearly 8%, sharply underperforming the broader healthcare sector (XLV closed modestly lower) and the S&P 500 (which edged higher). The selloff appears tied to profit-taking and sector rotation pressure, as the stock had surged roughly 70% over the prior year driven by its landmark Phase 3 HAELO trial success for lonvo-z in hereditary angioedema and the FDA's lifting of clinical holds on its ATTR program. Wedbush recently maintained a Neutral rating while raising its price target to $17—near current levels—suggesting limited near-term upside in analyst consensus even as the rolling BLA submission and a planned 2027 U.S. launch keep longer-term catalysts intact.

-7.9339

July 10, 2026Intellia Therapeutics shares tumbled sharply, pulling back roughly 8% in above-average volume as a deteriorating geopolitical backdrop weighed on risk assets broadly, while Wedbush raised its price target on the stock to $17 from $12 but maintained a Neutral rating — a tepid endorsement that did little to arrest the slide. The sell-off comes despite a strong fundamental backdrop: the company's Phase 3 HAELO trial for lonvo-z in hereditary angioedema met all primary and secondary endpoints, a rolling BLA submission to the FDA is underway, and Jim Cramer recently flagged biotech as 'the hottest group in the market' amid a wave of M&A optimism — though escalating U.S.-Iran hostilities and renewed inflation fears are overshadowing sector tailwinds for now.

-8.3135

July 9, 2026Intellia Therapeutics shares declined amid a broad risk-off session driven by Trump declaring the U.S.-Iran ceasefire 'over,' which sent oil prices surging over 5% and rattled equity markets. The CRISPR biotech, which had rallied sharply earlier this year on strong Phase 3 HAELO trial data for lonvo-z in hereditary angioedema and a rolling FDA biologics license application, pulled back alongside broader market weakness, though the healthcare sector has been a relative outperformer recently. Biotech sentiment remains elevated with Jim Cramer calling the group 'the hottest in the market' amid M&A optimism, while analysts maintain a consensus target near $26–27, suggesting meaningful upside from current levels.

-3.385

Simply Wall Street · July 16, 2026Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing?Investing.com · July 16, 2026Intellia stock downgraded by Wolfe Research on valuation concernsKavout | AI · July 16, 2026Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short InterestIntellia Therapeutics · June 13, 2026Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaIntellia Therapeutics · May 11, 2026Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesInvesting News Network · May 11, 2026Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesSimply Wall Street · May 6, 2026ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In FocusStock Titan · April 29, 2026Gene-editing biotech Intellia prices stock sale for about $180M
Benzinga · July 16, 2026Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target
Benzinga · July 10, 2026Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17
Mt Newswire · July 9, 2026Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating
Benzinga · June 15, 2026Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Benzinga · June 15, 2026Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target
Benzinga · June 15, 2026Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Benzinga · June 15, 2026Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine
Benzinga · June 1, 2026Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Breaking Oral Presentation At EAACI Annual Congress 2026

Peers

S&P 500SPX · $7,457.69-1.01%CRISPR Therapeutics AGCRSP · $47.78-1.63%Editas Medicine, Inc.EDIT · $2.98+3.47%Beam Therapeutics Inc.BEAM · $27.53-3.03%Caribou Biosciences, Inc.CRBU · $1.65-0.60%BridgeBio Pharma, Inc.BBIO · $81.38+1.34%Sana Biotechnology, Inc.SANA · $3.15-0.63%Precision BioSciences, Inc.DTIL · $7.87-5.41%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%BioNTech SEBNTX · $91.48-0.09%Travere Therapeutics, Inc.TVTX · $56.71+2.59%